FLGR-242 15mg — Vial Spec, Reconstitution Math & COA
A 15mg vial of FLGR-242 provides a high-yield lyophilized unit tailored for extended in vitro protocols, cellular binding assays, and multi-sample preclinical series. This technical specification guide outlines reconstitution math across standard diluent volumes, aliquot management protocols, and analytical purity validation standards required for rigorous laboratory experimentation.
Quick answer
A 15mg vial of FLGR-242 provides a high-yield lyophilized unit tailored for extended in vitro protocols, cellular binding assays, and multi-sample preclinical series. This technical specification guide outlines reconstitution math across standard diluent volumes, aliquot management protocols, and analytical purity validation standards required for rigorous laboratory experimentation.
Key takeaways
- A 15mg vial of FLGR-242 contains 15 milligrams of highly purified, lyophilized synthetic peptide, typically structured as a uniform white cake sealed under inert argon atmosphere.
- At PX1 Research, peptide inventory is maintained under strict environmental controls to preserve molecular stability.
- Accurate concentration calculations are vital when preparing 15mg FLGR-242 stock solutions to ensure experimental reproducibility.
- Once a 15mg vial of FLGR-242 is reconstituted into a liquid state, repeated freeze-thaw cycles can cause peptide cleavage, aggregation, or hydrophobic surface adsorption.
15mg Fill Specification & Laboratory Overview
A 15mg vial of FLGR-242 contains 15 milligrams of highly purified, lyophilized synthetic peptide, typically structured as a uniform white cake sealed under inert argon atmosphere. This larger fill size is engineered specifically for research facilities conducting extended in vitro assays, high-throughput receptor binding studies, or longitudinal preclinical animal models requiring consistent dosing solutions from a single homogenous manufacturing batch. By utilizing a 15mg mass per unit, principal investigators can minimize lot-to-lot variance across multi-week protocol runs.
In laboratory settings, FLGR-242 is studied as a targeted peptide derivative designed to interact with specific transforming growth factor-beta (TGF-β) superfamily signaling pathways. Because experimental protocols often require microgram-to-milligram quantities across multiple culture plates or tissue assays, the 15mg format streamlines stock solution preparation while significantly reducing total vial handling and reconstitution steps.
Catalog Availability & Mass Options at PX1 Research
At PX1 Research, peptide inventory is maintained under strict environmental controls to preserve molecular stability. While a 15mg mass serves specialized high-volume assay requirements, research groups evaluating single-plate assays or pilot toxicity screens may require smaller standard mass configurations. Investigators seeking our standard research-grade preparations can review the primary FLGR-242 product page for current in-stock fill sizes.
If a specific research protocol demands custom 15mg fills or specialized batch sizes not currently listed on the public catalog, laboratory purchasing departments can request custom synthesis runs or explore options across our broader all peptides directory. All custom and standard mass configurations adhere to identical cGMP-compliant manufacturing procedures, ensuring equivalent purity and stability regardless of total vial mass.
FLGR-242 Reconstitution Mathematics for 15mg Vials
Accurate concentration calculations are vital when preparing 15mg FLGR-242 stock solutions to ensure experimental reproducibility. Depending on the assay requirements, researchers typically reconstitute 15mg of lyophilized powder using 1.0 mL, 2.0 mL, or 3.0 mL of sterile laboratory diluent, such as bacteriostatic water or sterile 0.9% sodium chloride.
Reconstituting a 15mg vial with 1.0 mL of diluent yields a highly concentrated working stock of 15.0 mg/mL (equivalent to 15.0 µg/µL). Adding 2.0 mL of diluent produces a working solution of 7.5 mg/mL (7.5 µg/µL), which balances volumetric accuracy with liquid handling convenience. Adding 3.0 mL of diluent produces a concentration of 5.0 mg/mL (5.0 µg/µL). For rapid verification of custom volumes, researchers should utilize our online reconstitution calculator to eliminate manual calculation errors before liquid delivery.
Aliquot Planning & Preventing Freeze-Thaw Degradation
Once a 15mg vial of FLGR-242 is reconstituted into a liquid state, repeated freeze-thaw cycles can cause peptide cleavage, aggregation, or hydrophobic surface adsorption. To preserve structural integrity over extended testing windows, laboratory personnel should immediately divide the primary stock into single-use microcentrifuge aliquots using polypropylene sterile tubes.
Working aliquots should be calculated based on the daily or weekly volumetric requirements of the planned assays. For example, if a daily cell culture assay requires 100 µg of FLGR-242, a stock reconstituted at 5.0 mg/mL (5.0 µg/µL) requires a 20 µL aliquot per working tube. Storing aliquots at -20°C or -80°C isolates the remaining compound from thermal fluctuations, ensuring that only the required working volume is thawed prior to benchtop application.
Molecular Mechanism & In Vitro Binding Targets
Preclinical literature classifies FLGR-242 among specialized peptide compounds evaluated for their capacity to modulate myostatin (GDF-8) and related activin receptor signaling cascades. In vitro assays demonstrate that myostatin functions as a negative regulator of muscle tissue accretion, operating via ActRIIB receptor binding and downstream Smad2/3 phosphorylation. Research compounds designed around this pathway seek to competitively inhibit ligand binding, thereby preserving intracellular signaling activity in cellular models.
In vitro data indicate that FLGR-242 exhibits affinity toward specific cysteine-rich domains within regulatory proteins. Preclinical rodent models investigating skeletal muscle hypertrophy and metabolic degradation utilize these target interactions to measure changes in protein synthesis rates, gene expression profiles, and satellite cell activation without altering baseline endocrine functions.
Comparative Analysis with Related Myostatin Pathway Modulators
When designing comparative preclinical experiments, investigators frequently evaluate FLGR-242 alongside other established modulators within the myostatin inhibitors research class. Understanding structural differences between these agents allows researchers to select the precise molecular tool required for their specific tissue or cell assay.
For instance, follistatin 315 represents an endogenous glycosylated protein with broad binding affinity for activin A and myostatin, whereas FLGR-242 is a synthesized fragment optimized for targeted binding kinetics. Similarly, compounds like ace-031 function as soluble fusion proteins (ActRIIB-Fc) that act as decoy receptors. FLGR-242 provides a distinct peptide structure that allows researchers to analyze ligand-receptor dissociation rates without the confounding steric mass of immunoglobulin Fc domains.
Lot-Matched Analytics & COA Verification Standards
To ensure analytical rigor, every batch of FLGR-242 manufactured for PX1 Research undergoes stringent third-party testing in an ISO 17025 accredited analytical laboratory. Quality control protocols verify peptide identity, sequence correctness, chemical purity, and biological contaminant limits prior to catalog release.
High-Performance Liquid Chromatography (HPLC) is employed to confirm purity levels exceeding 99.0%, while Mass Spectrometry (MS) verifies precise molecular mass matching theoretical molecular weight. Additionally, bacterial endotoxin testing via Chromogenic LAL assays confirms levels remain strictly under <0.01 EU/mg, preventing unspecific inflammatory responses in sensitive cell cultures. Researchers can inspect and download verified lot certificates directly through our public COA portal.
Storage Protocols & Stability Parameters
Lyophilized FLGR-242 15mg vials exhibit optimal stability when stored in dark, desiccated environments at -20°C for short-term holds or -80°C for long-term storage spanning up to 24 months. Light exposure and moisture ingress represent primary degradation threats to lyophilized peptide cakes.
Following reconstitution with sterile bacteriostatic water containing 0.9% benzyl alcohol, liquid working stocks may be refrigerated at 2°C to 8°C for up to 28 days. If reconstituted with unpreserved sterile water or PBS, working solutions must be used immediately or frozen into micro-aliquots at -80°C. For comprehensive storage parameters and research application whitepapers, consult the PX1 research library hub.
Selecting the Optimal Vial Quantity for Research Frameworks
Choosing between a 15mg vial spec and smaller 2mg or 5mg units depends primarily on the scale and duration of the research project. Small-scale screening assays or initial solubility checks benefit from lower mass vials to limit reconstituted liquid storage times. Conversely, high-throughput microplate assays or multi-animal cohort studies achieve superior internal consistency when using 15mg vials derived from a single production lot.
For large academic institutions or corporate laboratories planning high-volume research pipelines, purchasing bulk or customized vial series optimizes unit economics while standardizing analytical baselines. Institutional buyers can learn more about bulk research pricing and institutional account structures on our dedicated wholesale portal.
Frequently Asked Questions
What is the primary advantage of selecting a 15mg FLGR-242 vial over smaller masses?
A 15mg vial allows laboratories conducting high-volume or long-term studies to reconstitute a single, large-volume stock solution. This eliminates lot-to-lot variance across multiple microplates or animal cohorts and simplifies working solution logistics.
How is the concentration of a 15mg FLGR-242 vial calculated after reconstitution?
Concentration is calculated by dividing total mass (15mg) by diluent volume (mL). Reconstituting with 1 mL yields 15 mg/mL (15 µg/µL); 2 mL yields 7.5 mg/mL (7.5 µg/µL); 3 mL yields 5 mg/mL (5 µg/µL).
What diluents are recommended for FLGR-242 reconstitution in laboratory research?
Sterile bacteriostatic water (containing 0.9% benzyl alcohol) is recommended for multi-use liquid stocks kept refrigerated up to 28 days. For immediate single-use assays or sensitive cell cultures where preservatives interfere, sterile 0.9% saline or sterile water for injection is preferred.
Does PX1 Research perform endotoxin testing on FLGR-242 15mg vials?
Yes. All FLGR-242 lots undergo kinetic chromogenic LAL assays in an ISO 17025 accredited laboratory to verify endotoxin levels remain below <0.01 EU/mg, ensuring suitability for sensitive in vitro and in vivo models.
How should reconstituted FLGR-242 15mg stock solutions be stored?
Reconstituted liquid stock should be sub-aliquoted into single-use polypropylene tubes and stored at -20°C or -80°C to prevent freeze-thaw degradation. Working tubes kept at 2°C to 8°C should be used within the recommended stability window.
Where can researchers verify the HPLC purity report for a specific FLGR-242 lot?
Lot-matched Certificates of Analysis (COAs) detailing HPLC purity chromatograms and Mass Spectrometry identity graphs are publicly accessible via the PX1 Research COA search directory.
Can FLGR-242 15mg vials be supplied for human therapeutic or medical use?
No. All compounds supplied by PX1 Research, including FLGR-242, are manufactured strictly for laboratory research, in vitro investigation, and preclinical experimentation. They are never for human, clinical, or veterinary use.
What should a research facility do if the 15mg vial size is out of stock?
If the 15mg size is unavailable, researchers can purchase multiple standard-sized vials (such as 5mg units) from the FLGR-242 product page or contact institutional support for custom synthesis and bulk scheduling.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.